



Provincial Health Services Authority

University of British Columbia  
BC Cancer Research Ethics Board

**UBC BC Cancer REB**

**UBC BC Cancer Research Ethics Board**

Fairmont Medical Building  
750 West Broadway, Suite 1315  
Vancouver, B.C. V5Z 1J3  
Tel: (604) 877-6284 Fax: (604) 708-2132  
Email REB Admin: [reb@bccancer.bc.ca](mailto:reb@bccancer.bc.ca)  
Website: [www.bccancer.bc.ca](http://www.bccancer.bc.ca) > Research Ethics  
RISe: <https://rise.ubc.ca>

**UBC BC CANCER RESEARCH ETHICS BOARD MEMBERSHIP LIST**

**List #79, effective August 15, 2022**

**UBC BC Cancer Research Ethics Board (REB) institution or organization (IORG) number: IORG0003172**  
**UBC Federal Wide Assurance Number for U.S. government studies: FWA00001149**  
**UBC BC Cancer REB IRB Registration Number: IRB00003797**

UBC BC Cancer REB VOTING MEMBER Gender/Canadian Citizenship or Permanent Resident		REB POSITION (Alternate Designation)	HIGHEST DEGREE(S)	PRIMARY SCIENTIFIC or NON SCIENTIFIC SPECIALITY	BC Cancer AFFILIATION	QUOROM DESIGNATION*
1.	<b>Dr. Karen Gelmon</b> Female/Yes	Voting Member Chair	MBBS	Medical Oncology	Yes	S
2.	<b>Dr. Vivien Bramwell</b> Female/Yes	Voting Member Vice-Chair	PhD/MBBS	Medical Oncology	Yes	S
3.	<b>Dr. Holly Longstaff</b> Female/Yes	Voting Member (Alternate for J. Gill)	PhD	Bioethics	No	E, C, N
4.	<b>Ms. Jo-Ann Isaacson</b> Female/Yes	Voting Member	n/a	Community Member	No	C, N
5.	<b>Dr. Doran Ksienski</b> Male/Yes	Voting Member	MD	Medical Oncology	Yes	S
6.	<b>Dr. Heather Sutherland</b> Female/Yes	Voting Member	MD	Medical Oncology/Hematology	Yes	S
7.	<b>Dr. Isabelle Vallieres</b> Female/Yes	Voting Member	MD	Radiation Oncology	Yes	S
8.	<b>Ms. Sylvie Labelle</b> Female/Yes	Voting Member	MSc	Pharmacy	Yes	S
9.	<b>Dr. Alice Hawkins Virani</b> Female/Yes	Voting Member(Alternate for J Gill)	PhD	Bioethics/Human Genetics	No	E, C, S
10.	<b>Dr. Ardis Krueger</b> Female/Yes	Ad Hoc Member	ND	Complementary and Alternative Medicine	No	S, H, C
11.	<b>Dr Aalok Kumar</b> Male/Yes	Voting Member	MD	Medical Oncology	Yes	S

12.	<b>Dr Nina Preto</b> Female/Yes	Voting Member (Alternate for J Gill)	PhD	Bioethics	Yes	E, C, N
13.	<b>Dr Sharlene Gill</b> Female/Yes	Voting Member	MD	Medical Oncology	Yes	S
14.	<b>Ms Julie Gibson</b> Female/Yes	Voting Member	JD	Law	No	L
15.	<b>Ms Patricia (Pat) Evans</b> Female/Yes	Voting Member (Alternate for J Isaacson)	BA	Community Member	No	C
16.	<b>Ms Elizabeth Kinney</b> Female/Yes	Voting Member (Alternate for J Gibson)	JD	Law	No	L
17.	<b>Dr Anita Ho</b> Female/Yes	Voting Member (Alternate for J Gill)	PhD	Bioethics	No	E
18.	<b>Mr Matthew Voell</b> Male/Yes	Voting Member (Alternate for J Gibson)	JD	Law	No	L
19.	<b>Mr Neil Hain</b> Male/Yes	Voting Member (Alternate for J Gibson)	LLB	Law	No	L
20.	<b>Ms Julia Gill</b> Female/Yes	Voting Member (Alternate for J Gill)	MHSc	Bioethics	No	E
21.	<b>Dr Brandon Bernard</b> Male/Yes	Voting Member	MD/MPH	Medical Oncology	Yes	S
22.	<b>Dr Krista Noonan</b> Female/Yes	Voting Member	MD	Medical Oncology	Yes	S
23.	<b>Dr. Anna Hayden</b> Female/Yes	Voting Member	MD	Hematology	Yes	S
24.	<b>Dr Jane Ingman-Baker</b> Female/Yes	Voting Member (Alternate for J Gibson)	LLB, PhD	Law	No	L
25.	<b>Dr. Hamid Raziee</b> Male/Yes	Voting Member	MD	Radiation Oncology	Yes	S
26.	<b>Ms. Tamsin Tarling</b> Female/Yes	Ad Hoc Member	MSc	Scientific (Biobanking)	Yes	S
27.	<b>Ms. Brittney Schichter</b> Female/Yes	Voting Member (Alternate for J Gill)	JD	Bioethics	No	E

\*A quorum comprises a minimum of five separate members from groups 1-4 with one from group 2-4 fulfilling group 5 voting in favour.

- (1) at least two members with broad expertise in biomedical research; (Scientific): **S**
- (2) at least one member knowledgeable in the ethics of scientific research: **E**
- (3) at least one member knowledgeable in law relevant to scientific research: **L**
- (4) at least one member from the community who has no affiliation with the institution: **C**
- (5) at least one member whose specialty is non-scientific (may be one of the members from groups 2-4): **N**
- (6) at least one member knowledgeable in therapeutic natural health products (ad hoc for review of therapeutic natural health products) **H**

**Changes reflected in this document:**


- Added: Ms. Brittney Schichter

FOR ALL RESEARCH CONDUCTED UNDER THIS ASSURANCE, THE UBC BC CANCER REB CHAIRPERSON HEREBY ATTESTS THAT, EXCEPT WHERE SPECIFICALLY WAIVED OR ALTERED BY THE REB UNDER 45 CFR 46.116(c), 46.116(d), or 46.117(c), THE REB WILL UPHOLD THE REQUIREMENTS OF 45 CFR 46 FOR WRITTEN INFORMED CONSENT, IN NONEXCULPATORY LANGUAGE UNDERSTANDABLE TO THE SUBJECT (OR THE SUBJECT’S LEGALLY AUTHORIZED REPRESENTATIVE), INCLUDING THE FOLLOWING BASIC ELEMENTS PER 45 CFR 46.116(a/b):

- (1) IDENTIFICATION AS RESEARCH PURPOSES, DURATION, AND PROCEDURES; PROCEDURES WHICH ARE EXPERIMENTAL;
- (2) REASONABLY FORESEEABLE RISKS OR DISCOMFORTS;
- (3) EXPECTED BENEFITS TO THE SUBJECT OR OTHERS;
- (4) ALTERNATIVE PROCEDURES OR TREATMENTS;
- (5) EXTENT OF CONFIDENTIALITY TO BE MAINTAINED;
- (6) WHETHER COMPENSATION OR MEDICAL TREATMENT ARE AVAILABLE IF INJURY OCCURS (IF MORE THAN MINIMAL RISK)
- (7) WHOM TO CONTACT FOR ANSWERS TO QUESTIONS ABOUT THE RESEARCH, SUBJECT’S RIGHTS, AND RESEARCH-RELATED INJURY;
- (8) PARTICIPATION IS VOLUNTARY, REFUSAL TO PARTICIPATE WILL INVOLVE NO PENALTY OR LOSS OF BENEFITS TO WHICH THE SUBJECT IS ENTITLED; SUBJECT MAY DISCONTINUE AT ANY TIME WITHOUT PENALTY OR LOSS OF BENEFITS TO WHICH SUBJECT IS ENTITLED;
- (9) WHEN APPROPRIATE, ADDITIONAL ELEMENTS PER 45 CFR 46.116(b).

**AS UBC BC CANCER REB CHAIRPERSON, I HEREBY SO ATTEST:**

SIGNATURE:



Dr. K Gelmon

DATE:

August 15, 2022

PHONE:

(604) 877-6284

ADDRESS:

750 West Broadway, Suite 1315  
Vancouver, B.C. V5Z 1J3